Core Viewpoint - Kewaunee Scientific Corporation has demonstrated significant growth in both revenue and earnings for the fourth quarter and fiscal year 2025, outperforming the S&P 500 index during the same period [1][2][3]. Revenue & Earnings Performance - Fiscal fourth-quarter net sales increased by 36.1% to $77.1 million from $56.7 million year-over-year [2]. - Adjusted diluted earnings per share (EPS) rose by 25.8% to $1.95 from $1.55 [2]. - For fiscal 2025, net sales totaled $240.5 million, an 18% increase from $203.8 million in the previous year [3]. - Adjusted diluted EPS for the year rose by 28.2% to $5.37 from $4.19 [3]. Segment Highlights - Domestic operations saw a 54.7% increase in fiscal fourth-quarter sales to $55.5 million from $35.9 million [4]. - International sales grew by 3.9% year-over-year in the fiscal fourth quarter to $21.7 million [5]. - The corporate segment reported an adjusted EBITDA loss of $1.4 million, widening from a loss of $956,000 the previous year [6]. Management Commentary - The CEO attributed the strong performance to effective strategy execution and heightened customer demand [7]. - The company acknowledged macroeconomic challenges but highlighted its adaptable culture and partnerships as strengths [8]. Drivers Behind the Results - The acquisition of Nu Aire significantly contributed to revenue and earnings growth, with adjusted operating profit reaching $9.8 million from $5.6 million in the prior year [9]. - The fiscal fourth-quarter adjusted gross profit surged by 69% to $24.7 million from $14.6 million [10]. Guidance - Management expressed optimism for continued growth through organic initiatives and potential future acquisitions [12]. Other Developments - Kewaunee completed the acquisition of Nu Aire on November 1, 2024, which is expected to generate long-term synergies despite short-term costs [13]. - The acquisition led to an increase in long-term debt and a rise in the debt-to-equity ratio to 0.99-to-1 from 0.70-to-1 the previous year [14].